PHARMACYCLICS INC Research and Development Expense (Excluding Acquired in Process Cost)
PHARMACYCLICS INC reported Research and Development Expense (Excluding Acquired in Process Cost) of $35.78 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2013-05-07
- PHARMACYCLICS INC research and development expense (excluding acquired in process cost) for the quarter ending 2013-03-31 was $35.78M, a 126.08% increase year-over-year.
- PHARMACYCLICS INC research and development expense (excluding acquired in process cost) for the quarter ending 2012-12-31 was $10.26M, a 15.03% decline year-over-year.
- PHARMACYCLICS INC research and development expense (excluding acquired in process cost) for the quarter ending 2012-09-30 was $19.07M, a 69.56% increase year-over-year.
- PHARMACYCLICS INC research and development expense (excluding acquired in process cost) for the quarter ending 2012-06-30 was $15.38M, a 55.80% increase year-over-year.
- PHARMACYCLICS INC research and development expense (excluding acquired in process cost) for fiscal 2012 was $54.54M, a 58.16% increase from fiscal 2011.
- PHARMACYCLICS INC research and development expense (excluding acquired in process cost) for fiscal 2011 was $34.48M, a 98.65% increase from fiscal 2010.
- PHARMACYCLICS INC research and development expense (excluding acquired in process cost) for fiscal 2010 was $17.36M.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month | Research and Development Expense (Excluding Acquired in Process Cost) 245 month |
|---|---|---|---|---|---|
| 2013-03-31 | $35.78M 10-Q · filed 2013-05-07 | $46.05M derived: sum of 2 quarters · filed 2013-05-07 | $65.12M derived: sum of 3 quarters · filed 2013-05-07 | $80.50M derived: sum of 4 quarters · filed 2013-05-07 | |
| 2012-12-31 | $10.26M derived: 10-KT 6 month − 10-Q 3 month · filed 2013-02-28 | $29.33M 10-KT · filed 2013-02-28 | $44.72M derived: sum of 3 quarters · filed 2013-02-28 | $60.55M derived: sum of 4 quarters · filed 2013-05-07 | |
| 2012-09-30 | $19.07M 10-Q · filed 2012-11-07 | $34.46M derived: sum of 2 quarters · filed 2013-02-28 | $50.28M derived: sum of 3 quarters · filed 2013-05-07 | $62.36M derived: sum of 4 quarters · filed 2013-05-07 | |
| 2012-06-30 | $15.38M derived: 10-KT 12 month − 10-Q 9 month · filed 2013-02-28 | $31.21M derived: sum of 2 quarters · filed 2013-05-07 | $43.29M derived: sum of 3 quarters · filed 2013-05-07 | $54.54M 10-KT · filed 2013-02-28 | |
| 2012-03-31 | $15.83M 10-Q · filed 2013-05-07 | $27.90M derived: sum of 2 quarters · filed 2013-05-07 | $39.15M 10-Q · filed 2012-05-10 | $49.03M derived: sum of 4 quarters · filed 2013-05-07 | |
| 2011-12-31 | $12.08M 10-Q · filed 2012-02-09 | $23.32M 10-Q · filed 2012-02-09 | $33.20M derived: sum of 3 quarters · filed 2013-02-28 | $41.85M derived: sum of 4 quarters · filed 2013-02-28 | |
| 2011-09-30 | $11.25M 10-Q · filed 2012-11-07 | $21.12M derived: sum of 2 quarters · filed 2013-02-28 | $29.77M derived: sum of 3 quarters · filed 2013-02-28 | $38.03M derived: sum of 4 quarters · filed 2013-02-28 | $388.96M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $9.88M derived: 10-KT 12 month − 10-Q 9 month · filed 2013-02-28 | $18.52M derived: sum of 2 quarters · filed 2013-02-28 | $26.78M derived: sum of 3 quarters · filed 2013-02-28 | $34.48M 10-KT · filed 2013-02-28 | |
| 2011-03-31 | $8.65M 10-Q · filed 2012-05-10 | $16.91M derived: sum of 2 quarters · filed 2012-05-10 | $24.61M 10-Q · filed 2012-05-10 | ||
| 2010-12-31 | $8.26M 10-Q · filed 2012-02-09 | $15.96M 10-Q · filed 2012-02-09 | |||
| 2010-09-30 | $7.70M 10-Q · filed 2011-11-08 | ||||
| 2010-06-30 | $17.36M 10-KT · filed 2013-02-28 |